Details checkedClinical trial listing onlyHistorical/discontinuedCheckedregistry

National Taiwan University Proton Pump Inhibitor SLC26A4 Hearing-Loss Study

Also known as: Proton pump inhibitor, Taquidine, Lansoprazole, SLC26A4 mutation, NCT00789061

Institution-led study

Primary source

Sponsor / Institution

Institution-led study

Program Type

Therapeutic

Modality

Small Molecule

Stage

Phase 2/3

Status

Unknown

Target Gene

SLC26A4

Route / Mode

Oral

Confidence

82%

Status Confidence

Status needs checking

Evidence Strength

Needs more support

Last Reviewed

2026-06-10

Geography

Taiwan

Population

genetic, fluctuating-hearing-loss

Trial IDs

Mechanism

Phase 2/3 academic study evaluating proton pump inhibitor therapy to prevent and treat acute fluctuating hearing loss in patients with SLC26A4 mutation.

Indications

Hearing Loss Sensorineural Hearing Loss Genetic Hearing Loss

Notes

Verified as an older academic repurposing study in SLC26A4-related fluctuating hearing loss. The registry status is Unknown and no current commercial program was established in this pass.

Evidence & Sources

1 structured sources

clinicaltrials

Supports: canonicalName, aliases, company, allCompanies, isIndustrySponsored, programType, modality, mechanism...

IDs: NCT00789061

Open

Key Events

2006-08-01

Registry lists study start for proton pump inhibitor in SLC26A4-related fluctuating hearing loss

Clinical Trials (1)

NCT00789061

Data Checks